Research topics
Biomarker research articles covering molecular signals, prediction tools, and measures used to study Crohn's disease, ulcerative colitis, or broader IBD.
Page 7 of 8 · 360 articles
The study links depleted fatty acid oxidation metabolites—especially butyrate—to impaired regulatory T cell development in IBD, suggesting a metabolic pathway that may influence immune tolerance and disease activity.
If therapies that restore intestinal barrier function can be reliably tested and measured, future treatments might be developed that specifically target barrier healing — a mechanism linked to symptom relief and possibly...
Patients and clinicians choosing first‑line biologic therapy for ulcerative colitis may find evidence here that vedolizumab can provide sustained clinical benefit and a favorable safety profile in a biologic‑naïve...
The study uses single-cell RNA sequencing to pinpoint genes and regulatory networks that might help explain IBD biology and suggest new biomarkers or repurposed drugs. That information could guide future research toward...
Cure8 found this source from Journal of gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Biomarkers, and Research and clinical trials. Open the original article...
New or improved fluorescent probes could enable more sensitive, noninvasive imaging of biochemical changes in the gut, which may aid research, earlier diagnosis, or monitoring of IBD and colorectal cancer.
Bowel urgency is a common, disruptive UC symptom; this trial analysis shows urgency improvements with etrasimod track with clinical remission, endoscopic improvement, better quality of life, and lower inflammatory...
IL-38 and a genetic variant (rs7599662) were linked to ulcerative colitis in this study, suggesting a possible new biomarker or therapeutic target. If validated, this could help researchers better understand UC...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
The study identifies candidate metabolites that may underlie gut–brain biochemical crosstalk during colitis, which could point to early biomarkers or mechanistic targets relevant to IBD-related brain effects.
A coordinated national research network can accelerate studies that matter to people with IBD—like tracking real-world disease patterns, testing diet and psychosocial approaches, improving monitoring with biomarkers and...
People with Crohn’s disease facing surgery may have varying risks of complications; better biomarkers and models could help tailor perioperative care and decision-making. The review signals active research toward more...
People with ulcerative colitis commonly experience depression; understanding whether the relationship is causal and which blood proteins might mediate it could help researchers develop biomarkers or new therapies...
Measuring both how severe inflammation is and how much of the colon is affected could give a fuller picture of disease burden than current focal endoscopic scores. For patients with UC, that may affect risk assessment...
Gut microbes produce small molecules that interact with the host. This study shows lower levels of certain microbial aromatic carboxaldehydes (I3A and 4HBA) in feces from people with Crohn’s disease, suggesting a...
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these...
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
People with long-standing ulcerative colitis face an increased risk of colorectal cancer; this study highlights PPARGC1A as a gene that may be downregulated early in that progression, which could eventually help identify...
The review shows increasing research linking ferroptosis to autoimmune diseases including IBD and ulcerative colitis, which may guide future biomarker and therapy research relevant to people with Crohn's disease or other...
A blood biomarker that rises with active ulcerative colitis could help patients and clinicians monitor disease activity without relying solely on invasive tests. This study reports that serum type 23 collagen ectodomain...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Researchers used genetics, microbiome, metabolism, and immune profiling together to nominate biological pathways and a four-gene signature that might help diagnose or explain ulcerative colitis. If validated later, these...
If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and...
People with UC have higher rates of low bone density, which raises fracture risk. This study links altered hormones (leptin, ghrelin, IGF‑1) and inflammation to lower BMD in UC, suggesting metabolic pathways that could...
This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...
New, non-invasive biomarkers and AI-driven multi-omic approaches could make diagnosis and treatment of IBD more precise, helping patients avoid invasive tests and improving chances of choosing effective therapies sooner.
Fatigue affects many people with Crohn’s even when inflammation looks controlled; recognizing it as a distinct target could change clinic assessments and treatment priorities.
Patients with small-bowel strictures face repeat procedures or surgery; this study suggests endoscopic stricturotomy outcomes differ by whether the stricture is from Crohn’s disease and that a simple blood marker (NLR)...
Small-bowel Crohn's disease often causes strictures and fistulas and typically needs more imaging and procedural care than colonic disease, so patients and clinicians should be aware of its distinct risks and treatment...
The study suggests measurable retinal and choroidal microvascular differences in people with IBD versus controls, which could point to systemic vascular effects of inflammation and offer noninvasive biomarker...
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
If validated, a blood test for cytotoxic CD4+ T cells at diagnosis could help predict who is less likely to respond to anti‑TNF drugs, potentially allowing earlier selection of alternative therapies for some children...
If correct, the paper points to a previously underappreciated immune cell (GzmK+ tissue-resident CD8+ T cells) as a potential driver of Crohn’s inflammation — which could lead to new biomarkers or therapies that work...
A reliable, accurate intestinal ultrasound could make routine monitoring easier, faster, and less costly than repeated MRI for people with Crohn’s disease. The study shows strong agreement between ultrasound scores and...
People with Crohn's disease often develop intestinal fibrosis and strictures that current drugs don't reverse; a growing drug pipeline aiming at anti‑fibrotic therapies could change future treatment options.
The study identifies colonic gene-expression programs that correlate with treatment failure, higher surgery rates, and perianal disease in Crohn’s — findings that could guide future prognostic tests and targeted...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
The study suggests that clinical remission on biologics can hide ongoing gut microbiome, metabolite, and epithelial abnormalities that may influence flare risk. This matters because focusing only on immune suppression...
Environmental pollutants are increasingly linked to Crohn's disease risk, especially when exposures occur in early life. Understanding these links may help explain rising IBD rates and guide future prevention research.
Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...
Fatigue is a common, burdensome symptom in Crohn's disease and hard to treat. This study links fatigue severity to differences in brain resting-state connectivity, suggesting brain–gut interactions may play a role.
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
A biomarker that appears before inflammation could help detect Crohn’s disease earlier or predict relapses. Understanding early immune changes may point to new preventive strategies rather than only treating inflammation...
The findings point to an immune-cell change that may happen before Crohn’s symptoms appear, which could help predict relapse or guide future therapies. That could eventually affect monitoring or new treatment strategies...
This study identifies a specific immune cell (γδ intraepithelial lymphocytes) that may fail before Crohn’s disease appears, which could help researchers develop early biomarkers or new therapies to prevent inflammation.
Research that maps neutrophil behavior in children with Crohn’s could reveal biological mechanisms and biomarkers relevant to disease progression or treatment response. Understanding neutrophil roles helps scientists...
